Trails blazed in medicine often bring controversy and even consternation. Breast care is no different. Since 1965, when the American College of Radiology formed the Committee on Mammography, advances in breast imaging and legislation to ensure its quality have largely centered on x-ray mammography.
Trails blazed in medicine often bring controversy and even consternation. Breast care is no different. Since 1965, when the American College of Radiology formed the Committee on Mammography, advances in breast imaging and legislation to ensure its quality have largely centered on x-ray mammography. Today, however, breast imaging centers employ a wide spectrum of imaging modalities that add clinical information to the diagnostic process. As Congress reviews the Mammography Quality Standards Act for reauthorization, it must take into account the continued evolution of breast imaging and ensure that additional breast imaging modalities are held to the same high standards as mammography.1-4
The MQSA, introduced in 1992 by Congress and appropriated for a five-year reauthorization cycle, hit a snag in 2003. Varying opinions on how best to improve the act without untoward effects led Congress to approve in 2004 legislation granting a one-time three-year reauthorization. Congress commissioned several studies to be conducted and planned to review their results in 2007 to determine if MQSA standards were in need of revision and/or expansion.2,3,5,6
The following are three of those studies:
The MQSA is approaching a new era in breast care delivery. The IOM study highlighted many issues in need of change. Centers of excellence with quality initiatives will set higher standards. More important, with the growing evolution of technology, the MQSA needs to regulate the newest imaging and diagnostic approaches in breast care to assure patient safety and high quality standards.
Currently, no standards are mandated for image-guided breast biopsies or other breast imaging technologies, such as ultrasound and MRI. There are three accreditation programs for breast ultrasound, for example, and the ACR's standards are by far the highest.10-12
What is needed is a single breast ultrasound accreditation program that reflects the highest standards to assure patients the best care. New technologies are gaining ground in the advancement of breast cancer diagnosis and interventions; however, these are not included under the auspices of the MQSA, because the imaging modalities do not use x-ray.
The MQSA, therefore, needs to evolve into the BIQSA-Breast Imaging Quality Standards Act-and move beyond what is to what should be. Breast imaging should be performed by dedicated physicians who have appropriate training and qualifications/accreditations, maintain high standards of care, and observe continuing quality review. The time to influence reauthorization is at hand, rather than waiting another five years for the next reauthorization. The BIQSA could be the start of a new direction that provides needed universal consistency in breast care.
Ms. Wagner is a retired ICU and home IV therapy nurse now working as a full-time patient advocate informing women of their breast biopsy choices and where to receive quality breast care. She can be reached at rwagner12@wi.rr.com.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.